S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates

NovoCure (NVCR) News Today

$14.12
-0.50 (-3.42%)
(As of 04/11/2024 ET)
SourceHeadline
markets.businessinsider.com logoBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution
markets.businessinsider.com - April 11 at 10:38 AM
MarketBeat logoNovoCure (NASDAQ:NVCR) Stock Rating Reaffirmed by Piper Sandler
americanbankingnews.com - April 11 at 5:18 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Given "Overweight" Rating at Piper Sandler
marketbeat.com - April 10 at 9:19 AM
marketbeat.com logoBaillie Gifford & Co. Sells 1,974,073 Shares of NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - April 10 at 8:34 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Trading 4.9% Higher
marketbeat.com - April 9 at 11:45 AM
businesswire.com logoNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
businesswire.com - April 5 at 7:00 AM
MarketBeat logoNovoCure Limited (NASDAQ:NVCR) Given Average Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - April 5 at 3:02 AM
MarketBeat logoNovoCure (NASDAQ:NVCR) Price Target Lowered to $42.00 at Wells Fargo & Company
americanbankingnews.com - April 4 at 4:10 AM
MarketBeat logoNovoCure (NASDAQ:NVCR) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - April 4 at 1:10 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Shares Gap Down Following Analyst Downgrade
marketbeat.com - April 3 at 1:36 PM
marketbeat.com logoWells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00
marketbeat.com - April 3 at 1:35 PM
markets.businessinsider.com logoNovoCure (NVCR) Receives a Buy from Wells Fargo
markets.businessinsider.com - April 3 at 1:35 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Shares Down 6.6%
marketbeat.com - April 2 at 3:17 PM
finance.yahoo.com logoNovocure to Report First Quarter 2024 Financial Results
finance.yahoo.com - April 1 at 10:35 AM
marketbeat.com logoQ4 2025 EPS Estimates for NovoCure Limited (NASDAQ:NVCR) Cut by Analyst
marketbeat.com - March 31 at 1:48 AM
fool.com logoWhy NovoCure Stock Soared 18.3% This Week
fool.com - March 30 at 6:34 AM
markets.businessinsider.com logoNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Target
markets.businessinsider.com - March 29 at 10:34 AM
marketbeat.com logoBrokers Offer Predictions for NovoCure Limited's Q4 2025 Earnings (NASDAQ:NVCR)
marketbeat.com - March 29 at 9:25 AM
fool.com logoWhy Novocure Stock Is Jumping Today
fool.com - March 28 at 11:50 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Trading Up 4.8% Following Analyst Upgrade
marketbeat.com - March 28 at 10:31 AM
seekingalpha.com logoNovoCure: Sell The METIS-Inspired Rally
seekingalpha.com - March 27 at 10:55 PM
marketbeat.com logoNovoCure's (NVCR) Neutral Rating Reiterated at Wedbush
marketbeat.com - March 27 at 10:10 PM
markets.businessinsider.com logoNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s Stock
markets.businessinsider.com - March 27 at 8:12 PM
msn.com logoNovocure's device shown to slow cancer progression in the brain in trial
msn.com - March 27 at 8:12 PM
markets.businessinsider.com logoPeeling Back The Layers: Exploring NovoCure Through Analyst Insights
markets.businessinsider.com - March 27 at 8:12 PM
marketwatch.com logoNovocure’s stock surges after positive results in brain-cancer trial
marketwatch.com - March 27 at 3:12 PM
markets.businessinsider.com logoNovocure Shares Rise After Phase 3 METIS Trial Met Primary Endpoint
markets.businessinsider.com - March 27 at 3:12 PM
msn.com logoNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
msn.com - March 27 at 3:12 PM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Price Target Raised to $24.00 at HC Wainwright
marketbeat.com - March 27 at 2:13 PM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Shares Gap Up to $13.07
marketbeat.com - March 27 at 11:47 AM
proactiveinvestors.com logoNovoCure device slows spread of lung cancer to brain in late-stage study; shares rise
proactiveinvestors.com - March 27 at 11:00 AM
marketwatch.com logoNovocure Shares Surge Premarket on Phase 3 TTFields Study
marketwatch.com - March 27 at 10:11 AM
investing.com logoNovocure shares jump after trial meets primary endpoint
investing.com - March 27 at 10:11 AM
msn.com logoNovocure's lung cancer therapy succeeds in late-stage trial
msn.com - March 27 at 10:11 AM
marketbeat.com logo
marketbeat.com - March 27 at 9:41 AM
businesswire.com logoZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
businesswire.com - March 27 at 9:29 AM
businesswire.com logoMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
businesswire.com - March 27 at 7:00 AM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Trading Down 6%
marketbeat.com - March 22 at 5:06 PM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00
marketbeat.com - March 20 at 10:39 AM
finance.yahoo.com logoNVCR Dec 2025 17.500 call
finance.yahoo.com - March 20 at 5:21 AM
finance.yahoo.com logoNVCR Jan 2026 20.000 call
finance.yahoo.com - March 20 at 5:21 AM
finance.yahoo.com logoNVCR Apr 2024 10.000 put
finance.yahoo.com - March 15 at 8:59 PM
finance.yahoo.com logoNVCR Apr 2024 17.500 call
finance.yahoo.com - March 15 at 8:59 PM
markets.businessinsider.com logoNovoCure’s Clinical Trial Results: Subgroup Promise Amidst Cautioned Market Outlook
markets.businessinsider.com - March 12 at 8:11 PM
marketbeat.com logoNovoCure (NASDAQ:NVCR) Shares Down 3.9%
marketbeat.com - March 12 at 12:53 PM
businesswire.com logoINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
businesswire.com - March 11 at 7:00 AM
marketbeat.com logoNovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from Analysts
marketbeat.com - March 11 at 2:32 AM
marketbeat.com logoSeven Eight Capital LP Acquires 71,989 Shares of NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - March 6 at 9:50 AM
marketbeat.com logoFederated Hermes Inc. Makes New $1.10 Million Investment in NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - March 5 at 7:22 AM
marketbeat.com logoPalo Alto Investors LP Purchases 82,157 Shares of NovoCure Limited (NASDAQ:NVCR)
marketbeat.com - March 1 at 10:27 AM
Get NovoCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Analysts Predict Price Tag for Gold to TRIPLE (Ad)

Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!

Read Colonial Metals' new Precious Metals Investment Guide.

NVCR Media Mentions By Week

NVCR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NVCR
News Sentiment

0.52

0.60

Average
Medical
News Sentiment

NVCR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NVCR Articles
This Week

8

5

NVCR Articles
Average Week

Get NovoCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NVCR) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners